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Abstract  
Depression is a common mental health disorder that affects at least 350 million 
people worldwide and exerts a negative effect upon a person’s physical, mental and 
social functions, and it is associated with an increased risk of premature death. The 
treatment of depression involves the use of antidepressants and selective serotonin 
inhibitors are currently the first line of treatment. In particular, fluoxetine is safe and 
effective in the treatment the disorder. It is one of the few antidepressants licensed 
for use in children under the age of 18 years in the UK. Fluoxetine is associated with 
fewer dose adjustments compared to other SSRIs and this simplifies therapy and 
may improve outcomes. However, fluoxetine induces a number of side effects like, 
nausea, insomnia, sexual dysfunction and its interaction with monoamine oxidase 
inhibitors can cause the serotonin syndrome. 
 
Introduction  
According to the World Health Organisation (WHO) report, major depression affects 
at least 350 million people worldwide ranking third on the list of global burden of 
disease (WHO 2008). It can occur at any age and its incidence is twice higher 
among women than men (Sclar et al. 2012). Sufferers and their families bear 
substantial individual, economic and social costs because the illness wields a 
negative effect upon the patient’s physical, mental and social functions. In fact, 
depression produces the greatest decline in health compared to long term physical 
conditions like angina, arthritis, asthma, and diabetes (Moussavi et al. 2007). From 
an economic perspective, the total annual cost of major depression was estimated to 
be 118 billion euros in Europe in 2004 alone, accounting for 33% of the total 
healthcare cost (Sobocki et al. 2006). These personal, social, familial and economic 
costs are a direct result of the symptoms of depression.  
The symptomatology of depression  
The symptoms of major depression can include low mood, impaired concentration, 
increased or decreased sleep, altered appetite or weight, psychomotor disturbance, 
fatigue, muscle tension and pain, social withdrawal, loss of interest in usual activities, 
crying, weeping feelings of guilt, worthlessness, suicidal ideation or 
behaviour(Thomas and Chan 2012). For the diagnosis of major depression, the 
symptoms of low mood and/or loss of interest should be present continuously in 
addition to four other symptoms for a period of 2 weeks or more (American 
Psychiatric Association 2013).  
Putative mechanism of depression  
Despite the well-defined symptomatology, major depression appears to be 
heterogeneous mental health disorder whose pathophysiology is currently unclear 
(Rahe et al. 2014). Environmental and personal biological vulnerabilities appear to 
play a significant part but precisely how these factors interact is not firmly 
established (Dichter et al. 2014) and this has given rise to several theories of 
depression. However, the theory that has direct relevance to current antidepressant 
treatment is the monoamine hypothesis. This theory simply suggests that depression 
is due to a reduction in concentration of monoamine neurotransmitters at the 
synapse in specific regions of the brain. These neurotransmitters are serotonin, 
noradrenaline and dopamine. The treatment of depression with antidepressants aims 
to reverse this monoamine neurotransmitter. The restoration of monoamines to 
normal levels corresponds with mood alleviation and this is the key function of 
antidepressants.  
Fluoxetine and the treatment of depression  
The use of antidepressants started in the 1952 with iproniazid, a monoamine-
oxidase inhibitor and later in 1955 with imipramine, a tricyclic antidepressant. 
However, the poor tolerability and toxicity of these drugs stimulated the search for 
other drugs with a better tolerability and safety profile. This led to the discovery of the 
Selective Serotonin Reuptake Inhibitors (SSRIs) and these drugs have become the 
most widely used groups of antidepressants (Hetrick et al. 2007). SSRI drugs 
operate mainly by selectively inhibiting the reuptake of serotonin in the synaptic cleft. 
As a class, they are ostensibly effective, safe in overdose and have a reduced side 
effect burden.  
Fluoxetine was one of the first SSRI to be marketed in 1987 and demonstrates an 
effectiveness that is at least equal to that of imipramine and other tricyclics (Pary et 
al. 1989). A review of 87 different randomised controlled trials with a total of 9087 
patients, concluded that fluoxetine is safe and effective in the treatment of 
depression and has advantages over first generation antidepressants in terms of 
safety (Rossi et al. 2004). These early findings are supported by a relatively recent 
Cochrane systematic review of 171 randomised controlled studies that found 
fluoxetine to be as efficacious and better tolerated compared to tricyclic 
antidepressants (Magni et al. 2013). In addition to the treatment of depression, some 
SSRIs and fluoxetine in particular are used for the treatment of obsessive 
compulsive disorder, panic disorder, bulimia nervosa.  
Fluoxetine is well absorbed after oral administration, with peak plasma 
concentrations observed after 6 to 8 hours and has an elimination half-life of 1 to 4 
days. It has an active metabolite, norfluoxetine which has an elimination half-life of 7 
to 10 days(AMA 1992). This extended half-life appears to protect against intermittent 
non-adherence and the occurrence of the serotonin discontinuation syndrome. 
Fluoxetine is associated with fewer dose adjustments compared to other SSRI and 
this simplifies therapy and may improve outcomes (Stokes and Holtz 1997). 
In the treatment of adults with major depression, a dose of 20 mg/day is 
recommended. If necessary, the dosage can be reviewed and adjusted within 3 to 4 
weeks of initiation of therapy and thereafter as judged clinically appropriate (Stokes 
and Holtz 1997). For those who show insufficient response to the 20mg dose, the 
dose can be increased to higher doses up to a maximum of 60mg/day (EMC 
Medicines 2015; Stokes and Holtz 1997). However, dose escalation may increase 
the potential for adverse side effects in some patients and therefore, dose 
adjustments should be made carefully on an individual patient basis with view to 
maintain the patient at the lowest effective dose. Patients with depression should be 
treated for a sufficient period of at least 6 months to ensure that they are free from 
symptoms (NICE, 2009). With respect to the older persons, fluoxetine is well 
tolerated and effective in treating depression but caution is recommended when 
increasing the dose (Stokes and Holtz 1997). The daily dose should generally not 
exceed 40mg though maximum recommended dose is 60mg/day (EMC Medicines 
2015). Fluoxetine is also widely used in the treatment of depression in children and 
adolescents. 
The treatment of children and adolescents with antidepressants has evoked lively 
debates about their safety in this population (Gibbons et al. 2007). There is black box 
warning against their use in children and adolescents because of their purported 
tendency to induce suicidal ideation and behaviour in this population according to at 
least one meta-analytic review (Sparks and Duncan 2013) although, at least one 
meta-analysis challenge this view (Gibbons et al. 2012). In spite of this dissent, the 
bulk of evidence in the extant literature suggest a link between suicidal ideation and 
the use of SSRIs in children and adolescents (Sparks and Duncan 2013). The 
situation is further complicated by the consistent finding from literature reviews 
examining the risks and benefits of SSRIs which consistently highlight the potentially 
serious consequences of untreated depression in children and adolescents (Eapen 
and Crncec 2012). On balance, these arguments seem to support SSRIs are an 
effective treatment option in children and adolescents with depression in clearly 
defined clinical situations (Hetrick et al. 2007). In this regard, NICE guidelines advise 
starting SSRIs in this population only in combination with a specific psychological 
treatment, and only if there has been no response to psychological treatment over 
four to six weeks. Close supervision of children and adolescents on SSRIs is 
necessary especially during the early stages of treatment stages and following dose 
changes (NICE 2015).  
Several SSRIs including citalopram and sertraline have been used in the treatment 
of depression in children and adolescents but according to a Cochrane review, 
fluoxetine is the only SSRI where there is consistent evidence from trials showing 
that it is effective in reducing symptoms of depression in both children and 
adolescents (Hetrick et al. 2007). Further, fluoxetine is the only antidepressant with 
marketing authorisation for use in children and young people aged between 8 and 18 
years (NICE 2015). 
Treatment should be initiated and monitored under specialist supervision (NICE 
2015). The starting dose is usually 10mg/day and dose adjustments should be made 
carefully, on an individual basis to maintain the patient at the lowest effective dose. 
After one to two weeks, the dose may be increased to 20mg/day and treatment can 
be continued for up to 9 weeks (EMC Medicines 2015; NICE 2015). Children with 
lower weight are likely to present with higher plasma levels; therefore therapeutic 
effect may be achieved with lower doses. For children who respond to treatment, the 
need for continued treatment after 6 months should be reviewed. If no clinical benefit 
is achieved within 9 weeks, treatment should be reviewed (EMC Medicines 2015).  
Fluoxetine induces a number of side effects including sexual dysfunction, insomnia, 
headache, diarrhoea and nausea. Its interaction with monoamine oxidase inhibitor 
(MAOI) can cause a fatal reaction, the serotonin syndrome. Therefore, treatment 
with fluoxetine should only be started 2 weeks after discontinuation of an irreversible 
MAOI (NICE 2009). Because fluoxetine is extensively metabolized by the liver and 
excreted by the kidneys, a lower dose is recommended in patients with significant 
hepatic dysfunction. Abrupt discontinuation of fluoxetine should be avoided and the 
dose should be gradually reduced over a period of at least four weeks in order to 
reduce the risk of withdrawal reactions(NICE,2009).  
Conclusion  
The prevalence and consequences of depression are clear and several treatments 
for the illness are available but the use of antidepressants remains central. SSRI in 
particular are used as the first line of treatment. Fluoxetine, one of the first SSRIs to 
be marketed has a relatively safe profile and is effective in the treatment of 
depression. In particular, fluoxetine has market authorisation for use in children 
between the ages of 8 and 18years old. However, fluoxetine induces a number of 
side effects and its interaction with MAOIs can cause the serotonin syndrome.  
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